New therapies for chronic obstructive pulmonary disease

Peter J Barnes

Chronic obstructive pulmonary disease (COPD) is common, affecting 6% of men and 4% of women over 45 years in the UK, and there is evidence that it is increasing throughout the world. It is responsible for 9% of certified sickness absence from work and imposes a large financial burden on the health service. COPD has an increasing worldwide prevalence and now ranks fifth in terms of global burden of disease. Treatment is often unsatisfactory and there are no currently available drug treatments that influence its progressive course. There is a widespread therapeutic nihilism, so that many patients with COPD are undertreated while others are treated as if they have asthma and this is often inappropriate. It is also important to remember that 5–10% of patients with COPD have never smoked and therefore there are other causal mechanisms apart from cigarette smoking.

In contrast to the enormous increase in our understanding of the pathophysiology of asthma, relatively little attention has been paid to COPD. The chronic airflow obstruction is due to a combination of airway disease which particularly affects small airways, and loss of lung elasticity due to enzymatic destruction of the lung parenchyma. It is likely that the latter predominates in most patients and, while this may be irreversible, it is likely to be preventable with suitable therapy.

There have been some recent advances in the therapy of COPD with improvement in bronchodilator therapy which is the mainstay of management. However, there is a need for the development of new therapies that prevent the progressive airflow obstruction in this condition.

New bronchodilators
Bronchodilators play an important role in the long term control of symptoms, but they do not alter the progression of COPD. The major advances have been in the development of long acting bronchodilators.

NEW ANTICHOLINERGICS
Anticholinergics are the bronchodilators of choice in the management of COPD and appear to be more effective than $\beta_2$ agonists. There have been important advances in muscarinic receptor pharmacology with the recognition of several subtypes of muscarinic receptors in airways which appear to serve different physiological functions. This has suggested that more selective muscarinic antagonists may have advantages over the existing non-selective drugs such as ipratropium bromide and oxitropium bromide. $M_3$ receptors appear to be localised to parasympathetic ganglia and blockade of these receptors results in reduced reflex bronchoconstriction. The bronchoconstrictor action of acetylcholine in human airways is mediated entirely via $M_3$ receptors. By contrast, $M_2$ receptors located at cholinergic nerve terminals inhibit the release of acetylcholine, thus acting as autoreceptors. Non-selective anticholinergics block $M_1$ and $M_3$ receptors, leading to bronchodilatation, as a result of relieving intrinsic cholinergic tone and inhibition of cholinergic reflex bronchoconstriction. However, by blocking prejunctional $M_2$ receptors this leads to an increase in acetylcholine release which may work against the post-junctional blockade of $M_2$ receptors, making these antagonists less efficient. It has been difficult to develop $M_2$ selective antagonists, but darifenacin (UK-88 525) is reported to be $M_1$ selective and is in clinical development. An $M_1/M_3$ selective antagonist, rispinepine, has also been developed that does not increase acetylcholine release, but no clinical studies have been reported. Another $M_1/M_3$ antagonist, revatropate (UK-112 166), is in clinical development as a bronchodilator for COPD. The most promising drug is tiotropium bromide (Ba 679) which has the unique property of kinetic selectivity, with rapid dissociation from $M_2$ receptors and slow dissociation from $M_3$ and $M_4$ receptors. Whether selective muscarinic antagonists will have advantages over existing non-selective drugs remains to be seen, however.

The most important property of tiotropium bromide is its very long duration of action. It has a high affinity and dissociates very slowly from muscarinic receptors in human lung and produces long term blockade of muscarinic receptors in human airway smooth muscle. This is reflected by the prolonged blockade of cholinergic neural constriction in human and guinea pig airways in vitro, with an effect lasting over eight hours in comparison with a duration of only one hour with ipratropium bromide. However, its effects on acetylcholine release are short lived and are similar to those seen with atropine and ipratropium bromide, thus confirming functional selectivity for $M_3$ rather than $M_2$ receptors. In clinical studies inhaled tiotropium bromide provides long term bronchodilatation and protection against cholinergic challenge in asthmatic subjects with effects lasting for more than three days. In studies of patients with COPD tiotropium bromide gives prolonged bronchodilatation lasting over 24 hours. This suggests that tiotropium brom-
Figure 1 Inflammatory mechanisms in COPD.

Cigarette smoke

CD8+ lymphocyte

Alveolar macrophage

Neutrophil chemotactic factors
Cytokines (IL-8)
Mediators (LTB4)

Neutrophil

α1-antitrypsin
SLPI
TIMPs

Alveolar wall destruction
(Emphysema)

Mucus hypersecretion
(Chronic bronchitis)

Neutrophil elastase
Matrix metalloproteinases

PROTEASES

PROTEASES

Anti-inflammatory treatments

COPD is characterised by inflammation of the airways. Bronchoalveolar lavage in patients with COPD shows increased numbers of neutrophils. Bronchial biopsy specimens have demonstrated an infiltration with mononuclear cells, CD4+ and, particularly, CD8+ T lymphocytes rather than neutrophils, suggesting that neutrophils may transit rapidly from the circulation into the airway lumen. Surprisingly, eosinophils may also be seen in stable COPD and increase to an even greater extent in exacerbations. Biopsy specimens of ex-smokers show a similar inflammatory process which suggests that, once established, inflammation may persist in the airway. Induced sputum in patients with COPD shows a predominance of neutrophils, even in ex-smokers, in sharp contrast to the increased levels of eosinophils seen in patients with asthma. There is an increased concentration of TNF-α in the sputum and this is consistent with the finding of increased TNF-α-like immunoreactivity in the airways of patients with COPD, particularly in exacerbations, and indicates that this cytokine may play a part in the inflammatory process. The role of neutrophils in the lumen of COPD airways is not yet established, but it is likely that the release of enzymes such as neutrophil elastase and matrix metalloproteinases (MMP) may contribute to the pathophysiology of the disease.

The mechanisms of the neutrophil inflammation in COPD are not yet certain but it is likely that neutrophil chemotactic factors are released into the airways from activated macrophages and possibly from epithelial cells and CD8+ T lymphocytes. Macrophages may play an important role in driving the inflammatory process in COPD and may release neutrophil chemotactic factors as well as proteolytic enzymes. Macrophage numbers are increased by 5–10-fold in the bronchoalveolar lavage fluid of patients with COPD and are concentrated in the centriacinar zones where emphysema is most marked. Furthermore, the number of macrophages and T lymphocytes, but not the number of neutrophils, in the alveolar wall is correlated with the amount of parenchymal destruction. Macrophages may be responsible for the continued proteolytic activity in the lungs of patients with emphysema. IL-8 is selectively chemoattractant to neutrophils and is present in high concentrations in induced sputum of patients with COPD, whereas its concentrations in those with asthma are not significantly increased. Furthermore, there is a significant correlation between the concentration of IL-8 and the extent of sputum neutrophilia which indicates that there may be a causal association.

Smoking cessation

Quitting smoking is the only strategy that has so far been shown to reduce the rate of decline in lung function in patients with COPD. Less than one third of patients are able to give up smoking, even with support. Nicotine replacement therapy may help some patients and transdermal patches and inhaled nicotine may be the most effective delivery systems, but continued administration of the addictive principle of cigarettes is an unpromising approach to smoking cessation and nicotine itself theoretically may have adverse cardiovascular effects. Another approach is to develop nicotine receptor antagonists. Behavioural intervention may be helpful in some patients. Pharmacological methods to reduce addictive behaviour have not so far been found to be effective and a controlled trial of the anxiolytic buspirone showed no benefit. The novel antidepressant bupropion (Zyban), which enhances central noradrenergic activity, is reported to increase smoking cessation markedly. In a recent study in which bupropion was given for seven weeks smoking cessation was 44% in the treatment group compared with 19% in the placebo group.

LONG ACTING β2 AGONISTS

Recent studies have shown that the long acting inhaled β2 agonists salmeterol and formoterol are beneficial in patients with COPD, resulting in improved lung function and symptom control. These treatments may be a useful addition to long acting anticholinergics. In one comparative study salmeterol given twice daily was significantly better in improving lung function and symptoms than ipratropium bromide given four times daily.

Barnes
may be secreted by macrophages, neutrophils, and by airway epithelial cells. TNF-α, which is also increased in the airways and in induced sputum of patients with COPD, may initiate the activation of the transcription factor nuclear factor-κB (NF-κB) which switches on the transcription of the IL-8 gene. Leukotriene B4 (LTB4) is also a potent chemoattractant for neutrophils in the airways and is increased in the sputum of patients with COPD and alveolar macrophages from patients with α1-antitrypsin deficiency secrete greater amounts of LTB4. Several approaches have been adopted to inhibit neutrophil inflammation (table 1).

CORTICOSTEROIDS

Because there is continued neutrophil inflammation in COPD it was thought that inhaled corticosteroids might prevent the progression of the diseases. However, there is little evidence that inhaled corticosteroids are beneficial in COPD, although there may be a few patients (~10%) who have some response to steroids and these patients should probably be regarded as having concomitant asthma. In a small study there was no significant effect on lung function of inhaled budesonide with or without oral prednisolone in terms of lung function or decline in lung function. A recent large study (EUROSCOP) in patients with mild COPD showed no overall effect of inhaled steroids (budesonide 400 μg twice daily) on the annual rate of decline in lung function, although some subgroups appeared to benefit. Neither inhaled nor oral steroids have any significant effect on neutrophil counts, granule proteins, or inflammatory cytokines in induced sputum, which is consistent with a lack of effect of corticosteroids on disease progression. However, there is a small effect on neutrophil chemotactic activity, presumably mediated via an effect on macrophage or epithelial cell function. This is in marked contrast to their efficacy in asthma and their ability to reduce eosinophil counts in induced sputum. However, corticosteroids are effective in treating acute exacerbations in COPD, presumably via some as yet undefined anti-inflammatory effect.

CHEMOKINE INHIBITORS

Several chemokines are involved in neutrophil chemotaxis. These belong to the CXC family of chemokines, the most prominent member of which is IL-8 which is markedly increased in the sputum of patients with COPD. Blocking antibodies to IL-8 and related chemokines inhibit certain types of neutrophil inflammation in experimental animals but have not yet been used in clinical studies. It is unlikely that a humanised monoclonal antibody would be suitable for long term therapy in patients with COPD. IL-8 works through a common receptor on neutrophils shared by other members of the CXC family (CXCR1) and an additional unique receptor (CXCR2). These chemokine receptors have the typical 7-transmembrane spanning structure common to G-protein coupled receptors. It may be possible to discover a non-peptidic inhibitor of these receptors by high throughput drug screening, but whether such drugs would be safe in long term dosing would require careful assessment. Another approach is to inhibit IL-8 synthesis. High concentrations of corticosteroids inhibit IL-8 gene transcription in airway epithelial cells, yet neither inhaled nor oral steroids reduce IL-8 levels in the sputum of patients with COPD, suggesting that it is relatively resistant to steroid inhibition in vivo.

Chemokines such as IL-8 are induced by the transcription factor NF-κB and there are several approaches to developing inhibitors for NF-κB. TNF-α levels are raised in the sputum of patients with COPD and this cytokine induces IL-8 in airway cells. Humanised TNF antibodies have now been developed for clinical use and have been found to be effective in other chronic inflammatory diseases such as rheumatoid arthritis and Crohn’s disease. Soluble TNF receptors that bind up released TNF have also been developed and are in clinical trials. This approach might be effective in the treatment of COPD.

LEUKOTRIENE B4 (LTB4) INHIBITORS

LTB4 is a potent chemoattractant for neutrophils and its concentrations are increased in the sputum of patients with COPD, probably being derived from alveolar macrophages. Several LTB4 receptor antagonists have now been developed and have been studied in clinical trials of asthma and inflammatory bowel disease, but not yet of COPD. A potent LTB4 antagonist (LY 293 111) is ineffective against allergen challenge in asthmatic patients, although interestingly it inhibits neutrophil recruitment into the airways during the late response, indicating its capacity to inhibit neutrophil chemotaxis in the airways. Several other potent LTB4 antagonists are now in development – for example, SC-53228, CP-105 696, and SB 201 146. LTB4 is synthesised by the enzyme 5′-lipoxigenase (5-LO) of which there are now several potent inhibitors. 5-LO inhibitors such as zileuton are now available in some countries for the treatment of asthma, since they also inhibit the synthesis of cysteinyl leukotrienes, but it is not certain whether they are effective in COPD.
molecules expressed on neutrophils and endothelial cells in the pulmonary and bronchial circulations. Neutrophil adhesion in response to chemotactic factors is characterised by expression of the β1 integrins CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-1) on the surface of the neutrophil and their interaction with their counter receptors, including intercellular adhesion molecule-1 (ICAM-1), on endothelial cells. E-selectin on endothelial cells also interacts with sialyl-Lewis x on neutrophils. Bronchial biopsy specimens of patients with COPD have shown increased expression of E-selectin on vessels and ICAM-1 on endothelial cells. Drugs that interfere with these adhesion molecules should therefore inhibit neutrophil inflammation in COPD. Monoclonal antibodies to CD18, ICAM-1, and E-selectin inhibit neutrophil accumulation in animal models of lung inflammation. However, there are concerns about this therapeutic approach for a chronic disease as an impaired neutrophilic response may increase the susceptibility to infections. Indeed, a congenital deficiency of β1 integrins results in leucocyte adhesion deficiency syndrome characterised by repeated septicemia.

PHOSPHODIESTERASE INHIBITORS
Inhibition of phosphodiesterases (PDE) increases the cyclic AMP content of neutrophils, resulting in reduced chemotaxis, activation, degranulation, and adhesion. The predominant isoenzyme is PDE4 and several PDE4 inhibitors are now in clinical development for asthma. It is not yet certain whether these drugs will be useful and many of the first generation PDE4 inhibitors have been limited by side effects such as nausea. In second generation PDE4 inhibitors such as SB 207 499 this may be less of a problem. Theophylline is a weak and non-selective PDE inhibitor and has inhibitory effects on neutrophil function in vitro. Aminophylline has an inhibitory effect on neutrophil chemotaxis in vitro. A recent study suggests that theophylline treatment in patients with COPD reduces neutrophil counts in induced sputum. Pentoxiphylline is another non-selective PDE inhibitor in clinical use that inhibits experimental neutrophil migration into the lungs, but it has not been evaluated in COPD. PDE4 inhibitors may also be effective because they not only have direct effects on neutrophil functions, but by inhibiting the release of chemotactic factors from alveolar macrophages. Again, PDE4 is the predominant subtype of PDE in human alveolar macrophages.

OTHER NEUTROPHIL INHIBITORS
Prostaglandin (PG) E2 is a potent inhibitor of the oxidative burst in neutrophils and its effects are mediated via EP2 receptors. Selective EP2 agonists such as misoprostol and butaprost may therefore be effective in suppressing neutrophil activation but have not been studied in COPD. Colchicine potently inhibits neutrophil activation, enzyme release, and chemotaxis by disrupting cytoskeletal microtubule structure. A controlled trial of colchicine in COPD showed some reduction in neutrophil elastase activity and in an observational study smokers who were treated with colchicine had a lower annual decline in lung function than smokers not treated with colchicine.

Macrolide antibiotics such as erythromycin, clarithromycin, and roxithromycin have inhibitory effects on neutrophil function that are independent of their antibiotic actions. This may be through some ill-defined membrane stabilising property and may account for the efficacy of macrolides in the treatment of diffuse panbronchiolitis, with a reduction in neutrophilic inflammation and elastase activity in bronchoalveolar lavage fluid.

SURFACTANT
Surfactant is important for preventing airway closure, but also has immunomodulatory effects and is important for normal mucus clearance. Cigarette smoking reduces surfactant production and this may contribute to the detrimental effects of cigarette smoking on airway function. This suggests that exogenous surfactant therapy might be beneficial in COPD, but the high cost of currently available preparations has made clinical studies difficult.

There are reports that ambroxol increases surfactant secretion in lungs of experimental animals but this has not been demonstrated in patients with COPD.

Antiproteases
There is considerable evidence that, in patients with COPD, there is an imbalance between proteases that digest elastin and those that protect against this. This suggests that either inhibiting these proteolytic enzymes or increasing antiproteases may be beneficial and theoretically should prevent the progression of airflow obstruction in COPD (table 2). Considerable progress has been made in identifying the enzymes involved in elastolytic activity in emphysema and in characterising the endogenous antiproteases that counteract this activity.

NEUTROPHIL ELASTASE INHIBITORS
Neutrophil elastase, a neutral serine protease, is a major constituent of lung elastolytic activity and also potently stimulates mucus secretion. In addition, neutrophil elastase induces IL-8 release from epithelial cells and therefore may perpetuate the inflammatory state. This has led to a search for neutrophil elastase inhibitors. Peptide inhibitors of neutrophil elas-
tase such as ICI 200 355, and non-peptide inhibitors such as ONO-5046, have been developed which have a high potency.73,74 These drugs inhibit neutrophil elastase-induced lung injury in experimental animals, whether given by inhalation or systemically,75 and inhibit neutrophil elastase-induced mucus secretion in vitro.76 There are few clinical studies with neutrophil elastase in patients with COPD. One study with oral MR889 administered for four weeks showed no overall effect on plasma levels of elastin-derived peptides or urinary levels of desmosine (markers of elastolytic activity), but these may not be sensitive markers.77 Although neutrophil elastase is likely to be the major mechanism mediating elastolysis in patients with α1-antitrypsin (α1-A T) deficiency, it may well not be the major elastolytic enzyme in smoking related COPD and it is important to consider other enzymes as targets for inhibition.

**CATHEPSIN INHIBITORS**

Neutrophil elastase is not the only proteolytic enzyme secreted by neutrophils. Cathepsin G and proteinase 3 have elastolytic activity and may need to be inhibited together with neutrophil elastase. Cathepsins (cathepsins B, L, and S) are also released from macrophages. Recently it has been found that suramin, a hexa-sulphonated naphthylurea which has been used as an anti-tumour drug, is a potent inhibitor of cathepsin G, proteinase 3, and neutrophil elastase.78

**MATRIX METALLOPROTEINASE INHIBITORS**

Matrix metalloproteinases (MMPs) are a group of over 20 closely related endopeptidases that are capable of degrading all of the components of the extracellular matrix of lung parenchyma, including elastin, collagen, proteoglycans, laminin and fibronectin. They are produced by neutrophils, but also by alveolar macrophages.79 Airway epithelial cells may also release MMPs.79 Recently, increased levels of collagenase (MMP-1) and gelatinase B (MMP-9) have been reported in bronchoalveolar lavage fluid of patients with emphysema.80 Bronchoalveolar macrophages from patients with emphysema express more gelatinase B and collagenase than cells from control subjects, suggesting that these cells rather than neutrophils may be the major source of these MMPs.81 Alveolar macrophages also express a unique MMP, macrophage metalloelastase (MMP-12),82 which plays a key role in murine models of emphysema.83 MMP-12 knock-out mice do not develop emphysema and do not show the expected increases in lung macrophages after long term exposure to cigarette smoke as occurs in normal animals.84 Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of these potent enzymes and three different TIMPs have now been characterised. There are several approaches to inhibiting MMPs.85 One approach is to enhance the secretion of TIMPs and another is to inhibit the induction of MMPs in COPD. MMPs may show increased expression with cigarette smoking through induction in response to inflammatory cytokines, oxidants, and other enzymes such as neutrophil elastase. It may be possible to prevent this induction with specific transcription inhibitors. Another approach is to develop specific inhibitors. Tetracyclines and hydroxamates such as batimastat (BB-94) and the orally active marimastat (BB-2516) are non-selective MMP inhibitors.86 Broad spectrum MMP inhibitors also inhibit an enzyme, TNF convertase, that inhibits the release of active TNF-α which may be an additional beneficial property. Side effects of such drugs may be a problem. More selective inhibitors of individual MMPs such as gelatinase B and macrophage metalloelastase are now in development and are likely to be better tolerated in chronic therapy. However, it is still not clear whether there is one predominant MMP in COPD or whether a broad spectrum inhibitor would be preferable.

**α1-ANTITRYPTPSIN**

The association of α1-A T deficiency with emphysema suggested that this endogenous inhibitor of neutrophil elastase may be of therapeutic benefit in COPD. Cigarette smoking may inactivate α1-A T, resulting in an opposed activity of neutrophil elastase and cathepsins. Extraction of α1-A T from human plasma is very expensive and extracted α1-A T is only available in a few countries (USA and Germany). This treatment has to be given intravenously and has a half life of only five days. This has led to the development of inhalated formulations.87 Nebulised α1-A T reduces neutrophil elastase activity in patients with cystic fibrosis.88 However, inhaled α1-A T is inefficient and expensive and could only be indicated in patients with severe α1-A T deficiency. Recombinant α1-A T with amino acid substitutions to increase stability may result in a more stable product. Gene therapy is another possibility using an adenovirus vector or liposomes, but there have been major problems in developing efficient delivery systems. There is a particular problem with gene transfer in α1-A T deficiency in that large amounts of protein (1–2 g) need to be synthesised each day. Human α1-A T has now been available for over 10 years but even in patients with severe α1-A T deficiency and emphysema there is only a marginal effect on the rate of decline in FEV1.89 There is no evidence that α1-A T treatment would halt the progression of COPD and emphysema in patients with normal plasma levels.

Other serum protease inhibitors (serpins) such as elafin may also be important in countering elastolytic activity in the lung. Elafin, an elastase-specific inhibitor, is found in bronchoalveolar lavage fluid and is synthesised by epithelial cells in response to inflammatory stimuli.90 Serpins may not be able to inhibit neutrophil elastase at the sites of elastin destruction due to the tight adherence of the inflammatory cell to connective tissue.91 Furthermore, these proteins may become inactivated by the inflammatory process and the action of oxidants so that they may not be able
to counteract elastolytic activity in the lung
adequately unless used in conjunction with
other therapies.32

SECRETORY LEUKOPROTEASE INHIBITOR
Secretory leukoprotease inhibitor (SLPI) is a
12 kDa serpin that appears to be a major
inhibitor of elastase activity in the airways. It
is secreted by epithelial cells90 and its secretion
is increased by corticosteroids.89 In vitro re-
combinant human SLPI is more effective at
inhibiting neutrophil mediated proteolysis than
α1-AT.91 Recombinant human SLPI given by
aerosolisation increases SLPI and anti-
neutrophil elastase activity in epithelial lining
fluid for over 12 hours, indicating potential
therapeutic usefulness.95

Mediator antagonists
ANTIOXIDANTS
There is considerable evidence that oxidative
stress is increased in patients with COPD and
that reactive oxygen species contribute to its
pathophysiology.96 Oxidants are present in ci-
garette smoke and are produced endogenously
by activated inflammatory cells including
neutrophils and alveolar macrophages. In-
creased production of endogenous oxidants is
demonstrated by the increased levels of hy-
drogen peroxide (H₂O₂) in expired condensates
from patients with COPD, particularly during exacer-
ations.97 There is also increased pro-
duction of nitric oxide in exhaled air.98 Oxidants
may contribute to the pathophysiology of
COPD in several ways, including damage of
serpins, potentiation of elastase activity, and
increased mucus secretion. In addition, oxidi-
ants activate the transcription factor NF-kB
which orchestrates the transcription of many
inflammatory genes including IL-8 and in-
ducible NO synthase.35

This suggests that antioxidants may be of use
in the treatment of COPD. N-acetyl cysteine
(NAC) provides cysteine for enhanced pro-
duction of glutathione (GSH) and has anti-
oxidant effects in vitro and in vivo. NAC inhibits
endotoxin-induced neutrophilic in-
flammation in rat lungs through inhibition of
NF-kB. In clinical studies NAC reduces the
number of exacerbations of COPD99 and in an
uncontrolled study appeared to reduce the rate
of decline in FEV₁ over a two year period.100
Although epidemiological studies have linked
COPD to poor intake of dietary antioxidants
such as vitamins C and E, there have been
no controlled trials of these vitamins in the
management of COPD.

It is likely that more effective antioxidants
will be developed for clinical use in the future.
Spin trap antioxidants such as α-phenyl-N-tert-
butyl nitronate are much more potent and inhibit
the formation of intracellular reactive oxygen
species by forming stable compounds.101 These
compounds are effective in animal models of
oxidative stress.102 They are now entering clini-
cal trials and their use in COPD should be
considered.

PROSTANOID INHIBITORS
Oxidative stress may result in the non-en-
zymatic formation of prostanoid mediators
(isoprostanes) directly from arachidonic acid
without the involvement of cyclo-oxygenase.103
There is increased formation of isoprostanes in
cigarette smokers104 and one isoprostane (8-
epi-prostaglandin F₂α) is a potent constrictor
of human airways, acting via stimulation of
thromboxane (TP) receptors.105 This suggests
that thromboxane receptor antagonists such as
seratrodast and Bay u3405 might be beneficial
in COPD.

The role of prostaglandins in COPD is un-
known. Inhalation of the cyclo-oxygenase in-
hibitor indomethacin is reported to reduce mucus
hyperssecretion in patients with
COPD.106 In patients with bronchiectasis indo-
methacin has an inhibitory effect on chemotaxis
of peripheral neutrophils but no effect on
neutrophils in sputum.107 It is likely that such
an effect may be mediated via inducible cyclo-
oxygenase (COX-2), and selective COX-2 in-
hibitors such as meloxicam and NS-398, which
may have a reduced tendency to cause gastro-
intestinal problems, are now in clinical de-
velopment.

Pulmonary vasodilators
Pulmonary hypertension due to chronic hyp-
oxia is a late complication of COPD in some
patients and leads to cor pulmonale. There
are no vasodilators that are selective for the
pulmonary rather than the systemic circulation,
so that vasodilator therapy with current agents
is potentially hazardous due to systemic hypo-
tension.108 The development of selective pul-
monary vasodilators depends on selective
delivery via the inhaled route or the de-
velopment of drugs that inhibit the mechanism
of hypoxic constriction and structural re-
modelling that occur in secondary pulmonary
hypertension. While prevention of structural
remodelling is desirable, it is not certain
whether relief of hypoxic vasoconstriction may
worsen the chronic hypoxia in COPD by in-
creased shunting.

PROSTACYCLIN ANALOGUES
Beraprost, an orally active form of prostacyclin,
is more stable and has been reported to have a
beneficial effect in pulmonary hypertension.109
Nebulised prostacyclin and its more stable ana-
logue, iloprost, are also reported to be effective
and the inhaled route appears to reduce the
systemic side effects seen with intravenous pro-
sacyclin.110

NITRIC OXIDE DONORS
Inhaled nitric oxide (NO) has been used for
some time as a selective pulmonary vasodilator
due to its short duration of action and in-
activation in the systemic circulation111 but it
is difficult to use over a prolonged period.
Several NO donor compounds have been de-
veloped but suffer from the disadvantage that
they cause systemic vasodilatation.
ENDOTHELIN ANTAGONISTS
Endothelin has potent constrictor effects on airway and pulmonary vascular smooth muscle and may play a role in COPD as its synthesis is increased by hypoxia. Endothelin-1 (ET-1) is strongly expressed in the pulmonary vascular endothelium of patients with pulmonary hypertension secondary to chronic hypoxia and urinary ET-1 excretion is increased in patients with COPD. ET-1, acting mainly via ET\(_{\alpha}\) receptors, induces fibrosis and hyperplasia of pulmonary vascular smooth muscle, implying a role in the pulmonary hypertension secondary to COPD. This suggests that ET-1 antagonists may prevent the development of pulmonary hypertension. Potent orally active non-peptide endothelin antagonists such as bosentan and SB 217 242 have now been developed. The non-selective antagonist bosentan and the ET\(_{\alpha}\) receptor antagonist BQ123 inhibit the development of pulmonary hypertension in rats after chronic hypoxia. Potent non-peptide selective orally active ET\(_{\alpha}\) antagonists such as PD 156 707 have also now been developed.

ANGIOTENSIN ANTAGONISTS
Angiotensin II is a potent pulmonary and airway constrictor acting via angiotensin (AT) receptors. Non-peptide inhibitors of AT\(_{1}\) receptors such as losartan have now been developed. Losartan inhibits hypoxic pulmonary vasoconstriction and the remodelling that occurs in the pulmonary circulation after chronic hypoxia. Losartan reduces pulmonary artery pressure in patients with COPD and therefore may be useful in preventing the progression of pulmonary hypertension and cor pulmonale in patients with severe COPD. An AT\(_{1}\) receptor antagonist PD 123 319 does not appear to affect the pulmonary response to hypoxia.

Mucoregulators
Increased secretion of mucus is found in all patients who smoke heavily, irrespective of airflow obstruction. However, recent epidemiological data suggest that mucus hypersecretion is significantly associated with a more rapid decline in FEV\(_1\) and increased hospitalisation of patients with COPD. This suggests that it may be important to develop drugs that inhibit the hypersecretion of mucus, although it will be important to find drugs that do not suppress the normal mucus secretion and impair mucociliary clearance. There are several types of mucoregulatory drugs in development.

TACHYKININ ANTAGONISTS
Tachykinins are potent stimulants of mucus secretion from submucosal glands and goblet cells in human and animal airways and act via NK\(_{1}\) receptors. In animal studies cigarette smoke induces airway mucus secretion via release of tachykinins from sensory nerves through a local axon reflex mechanism. NK\(_{1}\) antagonists markedly inhibit neurogenic mucus secretion and may therefore be useful as mucoregulators in cigarette smoke induced chronic bronchitis. Several potent non-peptide NK\(_{1}\) receptor antagonists such as CP-99 994 and SR 140 333 are now in clinical development and, while it is unlikely that they will be useful in asthma, they might have a role as regulators of mucus hypersecretion in COPD. A clinical trial of a non-selective peptide tachykinin antagonist FK-224 appeared to show some clinical benefit in patients with COPD, with a decrease in mucus production and coughing.

SENSORY NEUROPEPTIDE RELEASE INHIBITORS
Another approach to blocking tachykinin-mediated effects is to inhibit the release of tachykinins from sensory nerve endings via activation of pre-junctional receptors (fig 2). Of these receptors, \(\mu\)-opioid receptors are most effective and the \(\mu\)-opioid agonist morphine potently inhibits cigarette smoke-induced mucus secretion in animal airways. In human airways in vitro morphine inhibits mucus secretion activated via stimulation of sensory nerves. While morphine itself may not be useful as a therapeutic agent because of addiction, peripherally acting opioid agonists that do not cross the blood brain barrier, such as BW443, might be of use.

Many pre-junctional receptors appear to operate via the opening of a common potassium (K) channel, suggesting that K channel openers may be useful in blocking mucus secretion. Openers of ATP-dependent K channels such as cromakalim do, indeed, have an inhibitory effect on cigarette smoke-induced mucus secretion in animals.

MEDIATOR AND ENZYME INHIBITORS
Many mediators stimulate mucus secretion from submucosal glands and/or goblet cells and may therefore contribute to increased mucus secretion in COPD. It is unlikely, however, that any mediator antagonists such as anti-leukotrienes would have a major effect on mucus secretion. As noted above, neutrophil elastase and other proteases are potent stim-
ulants of submucosal gland and goblet cell secretion, suggesting that protease inhibitors may have inhibitory effects on mucus secretion, as well as inhibiting lung destruction. As noted above, inhalation of the cyclo-oxigenase inhibitor indomethacin is reported to reduce mucus hypersecretion in patients with COPD but long term trials of COX inhibitors have not been undertaken.

MUC gene suppressors
Several MUC genes that code for mucin synthesis have now been cloned. MUC2 and MUC5AC appear to be particularly important in airway mucus and MUC5AC may be up-regulated by inflammatory cytokines and inhibited by glucocorticoids. It is possible that drugs may be developed that inhibit the abnormally increased expression of MUC genes (predominantly MUC5AC in COPD) while preserving baseline secretion of MUC2. Such drugs, other than steroids, have not yet been developed.

Mucolytic agents
Several drugs were developed to reduce viscosity of mucus, thus aiding clearance from the respiratory tract. These drugs include cysteine derivatives such as N-acetyl cysteine, methyl cysteine, and carbocisteine which were effective in reducing mucus viscosity in vitro, but there is little convincing evidence that they increase mucus clearance in patients with COPD. DNase also reduces sputum viscosity, particularly when sputum is infected, as DNA is a major determinant of sputum viscosity. Although nebulised recombinant human DNase (dornase alfa) appears to improve the rheological properties of mucus in patients with cystic fibrosis, this has not been reported in COPD. It is possible that more effective mucolytic agents will be developed in the future.

Macrolide antibiotics
Erythromycin inhibits mucin secretion from human airways in vitro and appears to be interactive with dexamethasone. Erythromycin and clarithromycin also reduce endotoxin-induced mucus discharge from goblet cells in guinea pig trachea. This property does not appear to be related to its antibiotic activity and is consistent with other studies demonstrating an inhibitory action of erythromycin on cell secretion. There is a clinical case report of the efficacy of erythromycin in treating mucus hypersecretion and clarithromycin has been reported to reduce nasal secretion of mucus in patients with rhinitis. This suggests that the molecular mechanisms involved in these effects need to be defined and that studies in COPD may be indicated.

Drugs affecting remodelling
Since a major mechanism of airway obstruction in COPD is caused by loss of elastic recoil resulting from proteolytic destruction of lung parenchyma, it seems unlikely that this could be reversible by drug therapy, although it might be possible to reduce the rate of progression by preventing the inflammatory and enzymatic disease process. Retinoic acid increases the number of alveoli in developing rats and, remarkably, reverses the histological and physiological changes induced by elastase treatment. Retinoic acid activates retinoic acid receptors which act as transcription factors to regulate the expression of many genes. The molecular mechanisms involved and whether this can be extrapolated to humans is not yet known. Several retinoic acid receptor subtype agonists have now been developed that may have a greater selectivity for this effect.

Delivery systems
Bronchodilators are currently given as inhalers, either metered dose or dry powder inhalers, that have been optimised to deliver drugs to the respiratory tract. However, in emphysema the inflammatory process takes place in the lung parenchyma. This implies that a drug to be delivered by inhalation should have a lower mass median diameter so that there is preferential deposition in the lung periphery. It may be more appropriate to give the drug parenterally as it will need to reach the lung parenchyma via the pulmonary circulation, but parenteral administration may increase the risk of systemic side effects.

Future directions
There is a pressing need for the development of new drugs for the treatment of COPD. While preventing and quitting smoking is the obvious preferred approach, this has proved to be very difficult in the majority of patients. In addition, it is likely that the inflammatory process initiated by cigarette smoking may continue even when smoking has ceased. Furthermore, approximately 10% of patients with COPD are non-smokers. COPD may be caused by other environmental factors (pollutants, passive smoking, other inhaled toxins) or by development changes in the lungs.

It is important to identify the factors that determine why only 15% of smokers develop COPD. So far this is little understood, although it is likely that genetic factors are important. The only clearly established genetic risk factor for COPD is the ZZ allele of the α1-antitrypsin gene, although heterozygotes may be at slightly increased risk. There are also weak associations with α1-antichymotrypsin, α2-macroglobulin, and vitamin D binding protein. A polymorphism in the gene for the enzyme microsomal epoxide hydrolase responsible for the metabolism of reactive epoxide intermediates which may be generated in tobacco smoke has recently been found to be associated with a 4–5 fold increased risk of COPD and emphysema. It is likely that many other genetic polymorphisms will be discovered that will confer risk on smokers for the development of COPD and emphysema, so that it will even-
tually be possible to identify at risk patients and focus more effective therapies on them before lung function becomes too impaired.

Several new drugs are now in development that may be useful in COPD. These include LTB₄ antagonists and 5-lipoxygenase inhibitors, PDE4 inhibitors, new antioxidants and neutrophil elastase and MMP inhibitors. It will be difficult to demonstrate the efficacy of such treatments as determination of the effect of any drug on the rate of decline in lung function will require large studies over at least two years. There is an urgent need to develop surrogate markers such as analysis of sputum parameters (cells, mediators, enzymes) that may predict the clinical usefulness of such drugs. More research on the basic cellular and molecular mechanisms of COPD and emphysema are urgently needed to aid the logical development of new therapies for this common and important disease for which no effective preventative treatments currently exist.


et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.
New therapies for chronic obstructive pulmonary disease

147


New therapies for chronic obstructive pulmonary disease.

P J Barnes

Thorax 1998 53: 137-147
doi: 10.1136/thx.53.2.137

Updated information and services can be found at:
http://thorax.bmj.com/content/53/2/137.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Asthma (1782)
- Health education (1223)
- Smoking (1037)
- Tobacco use (1039)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/